FMO5 and metabolic dysfunction-associated steatotic liver disease: Berberine decreased oxidative (lower expression of Nox1 coding for NADPH-oxidase) and inflammatory events (lower expression of CD11c, a marker of activated macrophages) in the liver, leading to a lower hepatic injury (decrease in ALAT level in the plasma) in a genetic model of obesity and associated NAFLD, without improving steatosis and lipid homeostasis.